<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741012</url>
  </required_header>
  <id_info>
    <org_study_id>0412GARDASIL</org_study_id>
    <nct_id>NCT01741012</nct_id>
  </id_info>
  <brief_title>Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients</brief_title>
  <acronym>GARDASIL</acronym>
  <official_title>Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical neoplasia is increased in women with SLE most likely due to cervical infection with
      human papilloma virus (HPV). 70% of cervical cancer is caused by HPV types 16 and 18.
      Gardasil vaccine prevents cervical infection with HPV types 16 and 18. Thus lupus patients
      (who are susceptible to cervical cancer) may benefit from getting Gardasil vaccine which can
      prevent cervical cancer. Vaccines are generally safe and efficacious in SLE but no studies
      have been done on the use of this vaccine in SLE. The investigators hypothesize that Gardasil
      vaccine is safe and effective in SLE. This study will look at vaccine safety in patients with
      mild to moderate and minimally active or inactive SLE and measure how well they make
      protective antibodies after receiving the vaccine. In other words this will check how well
      the vaccine works in SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To gather safety information and adverse events on the use of Gardasil® in mild to moderate
      and minimally active or inactive SLE.

      To gather information on SLE disease activity flares after vaccination with Gardasil®.

      To gather information on the immunogenicity or development of protective anti HPV antibodies
      SLE after vaccination with Gardasil®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Participants With Adverse Events</measure>
    <time_frame>1,61,66,181,186,211,330 days</time_frame>
    <description>Frequency of participants with Vaccine site reactions, Frequency of participants with Non Vaccine Adverse Events,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Non Vaccine Adverse Events</measure>
    <time_frame>1,61,66,181,186,211,330 days</time_frame>
    <description>the number of non vaccine adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion by HPV Serotypes (HPV 6, HPV 11, HPV 16, HPV 18)as Assessed by Geometric Mean Antibody Titer</measure>
    <time_frame>Baseline (prevaccine) neutralizing anti HPV antibody titers at visit 1 and anti HPV antibody titers at 1 month post 3rd vaccine shot which is at 7 months in the study.</time_frame>
    <description>1. The percentage of HPV naive women who seroconverted by HPV serotypes was measured using Geometric Mean Titers for HPV serotypes HPV 6, HPV 11, HPV 16, HPV 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLE Disease Activity Flares</measure>
    <time_frame>1,61,66,181,186,211,330 days</time_frame>
    <description>SELENA-SLEDAI measurements &gt; or = to 2 The SELENA/SLEDAI is a validated instrument which is used to score disease activity and define flares with the SELENA-SLEDAI score range being 0-105, with 0 indicating inactive disease.The SELENA/SLEDAI instrument consists of 24 items, each with a definition of activity; there are 16 clinical items and 8 laboratory items. Although there are no set standards, inactive or minimal disease is generally reflected by a SELENA/SLEDAI score of less than or equal to 2 while more than minimally active disease is reflected by a score of &gt;2.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Gardasil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 ml single dose Gardasil vaccine given at three separate visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6</description>
    <arm_group_label>Gardasil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of systemic lupus erythematosis (SLE) by the American College of Rheumatology
        (ACR) Criteria.

        History of a positive antinuclear antibody (ANA) test result at any time in the past.

        40 participants with history of mild to moderate SLE disease Minimally active or inactive
        SLE disease, i.e., (Safety of Estrogens in Lupus Erythematosis National Assessment (SELENA)
        Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), SELENA-SLEDAI ≤2 at the start
        of the study.

        Age ≥ 18 years and ≤ 50 years. Gender: females Ability to provide informed consent.
        Maintenance Prednisone dose ≤ 15 mg/day. Plaquenil ≤ 400 mg/day.

        Exclusion Criteria:

        Hypersensitivity to any vaccine component Active infections including but not limited to
        human immunodeficiency virus (HIV positive), Hepatitis B or C, tuberculosis.

        Positive purified protein derivative (PPD) test results without evidence of prior treatment
        or administration of bacilli Calmette-Guerin (BCG) vaccine. A positive PPD is defined as ≥
        5 mm induration 24-38 hours after receiving 5TU (TU=tuberculin units) of PPD.

        Pregnancy or desire to become pregnant during the study period. Breast feeding. Inability
        to complete the immunization series. Received any blood product or component in the
        previous 6 months before enrollment.

        Received any inactivated vaccine product within 14 days before enrollment. Received any
        live vaccine product within 21 days before enrollment.

        Fever (temperature &gt; 100°F) at the time of enrollment. Inability to provided informed
        consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia J Dhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DCaTS-Clinical Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalresearch.med.wayne.edu/oncore.php</url>
    <description>Clinical Research Services Center, Wayne State University School of Medicine</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <results_first_submitted>March 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Patricia Dhar</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual data will be shared with any researcher, only aggregated de-identified data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gardasil</title>
          <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gardasil</title>
          <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Participants With Adverse Events</title>
        <description>Frequency of participants with Vaccine site reactions, Frequency of participants with Non Vaccine Adverse Events,</description>
        <time_frame>1,61,66,181,186,211,330 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Participants With Adverse Events</title>
          <description>Frequency of participants with Vaccine site reactions, Frequency of participants with Non Vaccine Adverse Events,</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vaccine site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non vaccine site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Non Vaccine Adverse Events</title>
        <description>the number of non vaccine adverse events</description>
        <time_frame>1,61,66,181,186,211,330 days</time_frame>
        <population>Number of non vaccine adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non Vaccine Adverse Events</title>
          <description>the number of non vaccine adverse events</description>
          <population>Number of non vaccine adverse events</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>non vaccine adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion by HPV Serotypes (HPV 6, HPV 11, HPV 16, HPV 18)as Assessed by Geometric Mean Antibody Titer</title>
        <description>1. The percentage of HPV naive women who seroconverted by HPV serotypes was measured using Geometric Mean Titers for HPV serotypes HPV 6, HPV 11, HPV 16, HPV 18</description>
        <time_frame>Baseline (prevaccine) neutralizing anti HPV antibody titers at visit 1 and anti HPV antibody titers at 1 month post 3rd vaccine shot which is at 7 months in the study.</time_frame>
        <population>The percentage of Human Papilloma Virus (HPV) naive women for HPV serotypes 6, 11, 16 and 18 that seroconverted</population>
        <group_list>
          <group group_id="O1">
            <title>HPV Serotype Naive Women</title>
            <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion by HPV Serotypes (HPV 6, HPV 11, HPV 16, HPV 18)as Assessed by Geometric Mean Antibody Titer</title>
          <description>1. The percentage of HPV naive women who seroconverted by HPV serotypes was measured using Geometric Mean Titers for HPV serotypes HPV 6, HPV 11, HPV 16, HPV 18</description>
          <population>The percentage of Human Papilloma Virus (HPV) naive women for HPV serotypes 6, 11, 16 and 18 that seroconverted</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 Serotype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 Serotype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 Serotype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 Serotype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SLE Disease Activity Flares</title>
        <description>SELENA-SLEDAI measurements &gt; or = to 2 The SELENA/SLEDAI is a validated instrument which is used to score disease activity and define flares with the SELENA-SLEDAI score range being 0-105, with 0 indicating inactive disease.The SELENA/SLEDAI instrument consists of 24 items, each with a definition of activity; there are 16 clinical items and 8 laboratory items. Although there are no set standards, inactive or minimal disease is generally reflected by a SELENA/SLEDAI score of less than or equal to 2 while more than minimally active disease is reflected by a score of &gt;2.</description>
        <time_frame>1,61,66,181,186,211,330 days</time_frame>
        <population>Number of patients who had a lupus flare defined by a SELENA -SLEDAI &gt; or = to 2</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil</title>
            <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>SLE Disease Activity Flares</title>
          <description>SELENA-SLEDAI measurements &gt; or = to 2 The SELENA/SLEDAI is a validated instrument which is used to score disease activity and define flares with the SELENA-SLEDAI score range being 0-105, with 0 indicating inactive disease.The SELENA/SLEDAI instrument consists of 24 items, each with a definition of activity; there are 16 clinical items and 8 laboratory items. Although there are no set standards, inactive or minimal disease is generally reflected by a SELENA/SLEDAI score of less than or equal to 2 while more than minimally active disease is reflected by a score of &gt;2.</description>
          <population>Number of patients who had a lupus flare defined by a SELENA -SLEDAI &gt; or = to 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for 18 months for each patient over the trial study period</time_frame>
      <desc>Adverse events (AEs) were collected by:
30 minute post vaccine unsolicited AEs--via 30 minute post vaccine AE recording sheet
7 day post vaccine solicited AEs-- via 7 day memory aide recording sheet and reminder phone call 72 to 96 hours after each vaccination
30 day post vaccine unsolicited AEs-- via 30 day diary and weekly phone calls.
weekly phone calls
once per month scripted phone calls</desc>
      <group_list>
        <group group_id="E1">
          <title>Gardasil</title>
          <description>Single treatment arm:
0.5 ml single dose Gardasil vaccine given at three separate visits
Gardasil: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6 Total of 7 study visits with vaccines given at visits 2,4 and 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting with hypertensive crisis</sub_title>
                <description>Nausea and vomiting due to gastritis with dehydration Hypertensive crisis due to non compliance with hypertension medications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath and itching after eating peanut butter</sub_title>
                <description>Allergic reaction to peanut butter.Pt had known allergy to peanuts</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain and arm pain</sub_title>
                <description>Chest pain and arm pain due to atypical non cardiac chest pain and a pinched nerve affecting the arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chest pain and shortness of breath with left sided numbness</sub_title>
                <description>Non cardiac chest pain due to fibromyalgia. Cardiac disease ruled out.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>chest pain non cardiogenic</sub_title>
                <description>Chest pain radiating down left arm due to DJD (degenerative joint disease) of the Cervical spine with radiculopathy Cardiac work up negative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>swollen left leg with ulcer</sub_title>
                <description>Edema with superficial laceration which healed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>unplanned pregnancy</sub_title>
                <description>Unplanned pregnancy. Patient chose to terminate the pregnancy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>unplanned pregnancy</sub_title>
                <description>unplanned pregnancy. Patient chose voluntary termination of pregnancy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pain, swelling and discharge of the right breast</sub_title>
                <description>Pain, swelling and discharge of the right breast due to a blocked duct</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic system disorders</sub_title>
                <description>There were 3 blood and lymphatic disorder non vaccine related adverse events in 3 patients</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>There were 2 cardiac disorder non vaccine related adverse events in 2 patients</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <description>There were 4 ear and labyrinth disorder non vaccine related adverse events in 3 patients</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <description>There were 3 eye disorder non vaccine related adverse events in 3 patients</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>There were 49 gastrointestinal non vaccine related adverse events in 18 patients</description>
                <counts group_id="E1" events="49" subjects_affected="18" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <description>There were 45 general disorder non vaccine related adverse events in 17 patients</description>
                <counts group_id="E1" events="45" subjects_affected="17" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders-other</sub_title>
                <description>There was one hepatobiliary disorder non vaccine related adverse event in one patient</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>immune system disorders</sub_title>
                <description>There were 4 immune system disorder non vaccine related adverse events in 4 patients</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections</sub_title>
                <description>There were 44 non vaccine related infectious adverse events in 21 patients</description>
                <counts group_id="E1" events="44" subjects_affected="21" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injury poisoning and procedural complications</sub_title>
                <description>There were 3 injury, poisoning and procedural complications in 3 patients</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>There were 8 metabolism and nutrition non vaccine related adverse events in 7 patients</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <description>There were 106 number of musculoskeletal non vaccine related adverse events in 34 patients</description>
                <counts group_id="E1" events="106" subjects_affected="24" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>neoplasms benign, malignant and unspecified (incl dysts and polyps)</sub_title>
                <description>There were 2 neoplasms benign, malignant, and unspecified non vaccine related adverse events in 2 patients</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervouus system</sub_title>
                <description>There were 102 Nervous system non vaccine related adverse events in 34 patients</description>
                <counts group_id="E1" events="106" subjects_affected="25" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy , puerperium and perinatal conditions</sub_title>
                <description>There were 2 pregnancy, puerperium and perinatal condition non vaccine related adverse events in 2 patients</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric disorders</sub_title>
                <description>There were 12 psychiatric disorder non vaccine related adverse events in 5 patients</description>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal and urinary disorders</sub_title>
                <description>There were 6 renal and urinary disorder non vaccine related adverse events in 6 people</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>reproductive system and breast disorders</sub_title>
                <description>There were 7 reproductive and breast non vaccine related adverse events in 6 patients</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory disorder</sub_title>
                <description>There were 29 respiratory non vaccine related adverse events in 12 patients</description>
                <counts group_id="E1" events="29" subjects_affected="12" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatologic</sub_title>
                <description>There were 45 dermatologic non vaccine related adverse events in 17</description>
                <counts group_id="E1" events="45" subjects_affected="17" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <description>There were 5 surgical and medical procedure non vaccine related adverse events in 3 patients</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vascular disorder</sub_title>
                <description>There were 18 vascular disorder non vaccine related adverse events in 10 patients</description>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. J. Patricia Dhar, MD, Principal Investigator</name_or_title>
      <organization>Wayne State University School of Medicine</organization>
      <phone>313-577-6011</phone>
      <email>pdhar@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

